关于赫梅林等人的评论：纳米干熔法——一种制备药物无定形固体分散体的新技术。2022年，，2145。 （原文中“2022, , 2145”表述似乎不太完整规范，可能影响准确理解，你可检查确认下原文信息）
Comment on Hermeling et al. Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions. 2022, , 2145.
作者信息
Miller Dave A, Kucera Sandra U, Ellenberger Daniel, Davis Daniel, Williams Robert O
机构信息
AustinPx, LLC, 111 W. Cooperative Way, Bldg. 3, Suite 300, Georgetown, TX 78626, USA.
College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA.
出版信息
Pharmaceutics. 2025 May 29;17(6):714. doi: 10.3390/pharmaceutics17060714.
Abstract
My colleagues and I are writing in response to an article published in the October 2022 issue of titled "Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions" [...].
摘要
我和我的同事撰写此信是为了回应发表在《[期刊名称]》2022年10月期上的一篇题为“纳米干熔融：一种用于制备药物无定形固体分散体的新技术”的文章。[......]
相似文献
1
Comment on Hermeling et al. Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions. 2022, , 2145.关于赫梅林等人的评论：纳米干熔法——一种制备药物无定形固体分散体的新技术。2022年，，2145。 （原文中“2022, , 2145”表述似乎不太完整规范，可能影响准确理解，你可检查确认下原文信息）
Pharmaceutics. 2025 May 29;17(6):714. doi: 10.3390/pharmaceutics17060714.
2
Reply to Miller et al. Comment on "Hermeling et al. Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions. 2022, , 2145".回复米勒等人。对“Hermeling等人。纳米干熔融：一种制备药物无定形固体分散体的新技术。2022年，，2145”的评论
Pharmaceutics. 2025 May 29;17(6):715. doi: 10.3390/pharmaceutics17060715.
3
species on palms - integrative taxonomic approach for species boundaries delimitation in the genus , with the description of .棕榈树上的物种——该属物种界限划分的综合分类学方法，以及对……的描述 。 （原文中“with the description of.”后面内容缺失，翻译可能不太完整准确）
Stud Mycol. 2024 Dec;109:487-594. doi: 10.3114/sim.2024.109.08. Epub 2024 Oct 23.
4
Tranexamic acid for percutaneous nephrolithotomy.氨甲环酸在经皮肾镜碎石术中的应用。
Cochrane Database Syst Rev. 2023 Oct 26;10(10):CD015122. doi: 10.1002/14651858.CD015122.pub2.
5
A Systematic Review on the Hazard Assessment of Amorphous Silica Based on the Literature From 2013 to 2018.基于 2013 年至 2018 年文献的无定形二氧化硅危害评估的系统评价。
Front Public Health. 2022 Jun 15;10:902893. doi: 10.3389/fpubh.2022.902893. eCollection 2022.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
7
Psychological and/or educational interventions for the prevention of depression in children and adolescents.预防儿童和青少年抑郁症的心理和/或教育干预措施。
Cochrane Database Syst Rev. 2004(1):CD003380. doi: 10.1002/14651858.CD003380.pub2.
8
Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients.提高实体器官移植受者免疫抑制剂药物依从性的干预措施。
Cochrane Database Syst Rev. 2022 Sep 12;9(9):CD012854. doi: 10.1002/14651858.CD012854.pub2.
9
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.利福昔明预防和治疗肝硬化患者肝性脑病。
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD011585. doi: 10.1002/14651858.CD011585.pub2.
10
Occupational therapy for cognitive impairment in stroke patients.脑卒中患者认知障碍的作业治疗。
Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD006430. doi: 10.1002/14651858.CD006430.pub3.
本文引用的文献
1
Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions.纳米干熔法：一种制备药物无定形固体分散体的新技术。
Pharmaceutics. 2022 Oct 9;14(10):2145. doi: 10.3390/pharmaceutics14102145.
2
Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity.在无定形固体分散体中制备热不稳定和剪切不稳定药物：平衡药物降解和结晶度。
Int J Pharm X. 2021 Jul 17;3:100092. doi: 10.1016/j.ijpx.2021.100092. eCollection 2021 Dec.
3
Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.药物非晶态固体分散体：制备策略综述
Acta Pharm Sin B. 2021 Aug;11(8):2505-2536. doi: 10.1016/j.apsb.2021.05.014. Epub 2021 Jun 5.
4
The effect of drug loading on the properties of abiraterone-hydroxypropyl beta cyclodextrin solid dispersions processed by solvent free KinetiSol® technology.载药比对无溶剂 KinetiSol®技术处理的阿比特龙-羟丙基-β-环糊精固体分散体性质的影响。
Eur J Pharm Biopharm. 2021 Aug;165:52-65. doi: 10.1016/j.ejpb.2021.05.001. Epub 2021 May 9.
5
and Behaviors of KinetiSol and Spray-Dried Amorphous Solid Dispersions of a Weakly Basic Drug and Ionic Polymer†.动力学溶液和喷雾干燥无定形固体分散体的弱碱性药物和离子聚合物的行为†。
Mol Pharm. 2020 Aug 3;17(8):2789-2808. doi: 10.1021/acs.molpharmaceut.0c00108. Epub 2020 Jul 6.
6
Improved Dissolution and Pharmacokinetics of Abiraterone through KinetiSol Enabled Amorphous Solid Dispersions.通过KinetiSol技术制备的阿比特龙无定形固体分散体改善其溶出度和药代动力学。
Pharmaceutics. 2020 Apr 14;12(4):357. doi: 10.3390/pharmaceutics12040357.
7
Homogeneity of amorphous solid dispersions - an example with KinetiSol.无定形固体分散体的均一性——以 KinetiSol 为例。
Drug Dev Ind Pharm. 2019 May;45(5):724-735. doi: 10.1080/03639045.2019.1569037. Epub 2019 Jan 25.
8
Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet.生成等效体外和体内性能的弱碱性利托那韦的弱酸性无定形固体分散体与 Norvir 片剂。
AAPS PharmSciTech. 2018 Jul;19(5):1985-1997. doi: 10.1208/s12249-018-1060-x. Epub 2018 Jun 4.
9
Expanding the Application and Formulation Space of Amorphous Solid Dispersions with KinetiSol®: a Review.用 KinetiSol®拓展无定形固体分散体的应用和剂型研究：综述。
AAPS PharmSciTech. 2018 Jul;19(5):1933-1956. doi: 10.1208/s12249-018-1007-2. Epub 2018 May 30.
10
Improved Vemurafenib Dissolution and Pharmacokinetics as an Amorphous Solid Dispersion Produced by KinetiSol® Processing.KinetiSol® 工艺制备无定形固体分散体提高维莫非尼的溶出度和药代动力学。
AAPS PharmSciTech. 2018 Jul;19(5):1957-1970. doi: 10.1208/s12249-018-0988-1. Epub 2018 Mar 14.
Zotero 插件